Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model

Cancer Research

Volumn 60, Issue 19, 2000, Pages 5456-5463

  Tillman, B W ^a   Hayes, T L ^a   DeGruijl, T D ^a   Douglas, J T ^a   Curiel, D T ^a  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CD8 ANTIGEN; VIRUS VACCINE;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; GENE THERAPY; GENE TRANSFER; IMMUNIZATION; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; UTERINE CERVIX CANCER; VACCINATION; VIRUS INFECTION; VIRUS VECTOR; WART VIRUS;

ADENOVIRIDAE; ANIMAL; ANTIGENS, CD40; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; EPITOPES; GENE TARGETING; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMAN; IMMUNOTHERAPY, ACTIVE; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS, HUMAN; PHENOTYPE; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0034306991     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Dendritic cells and the control of immunity
2. Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines
3. Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection
4. Retroviral transduction of human dendritic cells with a rumor-associated antigen gene
5. Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16 induced tumor cells
6. Therapy of murine tumors with tumor peptide pulsed dendritic cells: Dependence of T-cells, B7 costimulation, and Th1-associated cytokines
7. Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms
8. Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells
9. Gene based strategies for the immunotherapy of cancer
10. Dendritic cell therapy of cancer and HIV infection
11. Gene-modified dendritic cells for use in tumor vaccines
12. A comparison of gene transfer methods in human dendritic cells
13. Nonviral transfection of distinct types of human dendritic cells: High-efficiency gene transfer by electroporation into hematopoetic progenitor- but not monocyte-derived dendritic cells
14. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL
15. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens
16. Induction of antigen-specific antitumor immunity with adenovirus-transduced dendritic cells
17. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity
18. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5
19. Adenovirus endocytosis via α(v) integrins requires phosphoinositide-3-OH kinase
20. Integrins αvβ3 and αvβ5 promote adenovirus internalization but not virus attachment
21. Targeted gene delivery by tropism modified adenoviral vectors
22. Targeted adenovirus-mediated gene delivery to T cells via CD3
23. Differential susceptibility of primary and established human glioma cells to adenovirus infection: Targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer
24. Adenoviruses activate human dendritic cells without polarizing toward a T-helper type 1-inducing subset
25. Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector
26. Human papillomavirus E6 and E7: Proteins which deregulate the cell cycle
27. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective
28. Accumulation of human papillomavirus type 16 E7 protein bypasses G1 arrest induced by serum deprivation and by the cell cycle inhibitor p21
29. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells
30. The SCID but not the RAG-2 gene product is required for Sμ-Sε heavy chain class switching
31. Production of bispecific antibodies
32. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte-macrophage colony stimulating factor
33. Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells
34. Cytotoxic T-lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors
35. Cancer vaccines
36. Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA41g
37. Cellular immunity delimits adenoviral gene therapy strategies for the treatment of neoplastic diseases
38. Impairment of force generation after adenoviral-mediated gene transfer to muscle is alleviated by adenoviral gene inactivation and host CD8+ T-cell deficiency
39. CD40-CD40 ligand
40. The CD40 ligand: At the center of the immune universe
41. Help for cytotoxic T-cell responses is mediated by CD40 signaling
42. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell
43. T-cell help for cytotoxic T-lymphocytes is mediated by CD40-CD40L interactions
44. Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas
45. Fluorescent virions: Dynamic tracking of the pathway of adenoviral gene transfer vectors in living cells
46. Gene therapy death prompts review of adenovirus vector
47. Recombinant E1-deleted adenovirus-mediated gene therapy for cancer: Efficacy studies with p53 tumor suppressor gene and liver histology in tumor xenograft models
48. Adenovirus-mediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation, and neointimal hyperplasia
49. In vivo gene transfer into injured carotid arteries
50. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis
51. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy
52. CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge
53. Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T-lymphocyte epitopes in a string of beads fashion
54. Peptide vaccination with an anchor-replaced CTL epitope protects against human papillomavirus type 16-induced tumors expressing the wild-type epitope
55. Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic anti-tumor immunity
56. Differential binding of viral peptides to HLA-A2 alleles: Implications for human papillomavirus type 16 E7 peptide-based vaccination against cervical carcinoma
57. Cellular transformation by papillomavirus oncoproteins
58. Structure function analysis of the human papillomavirus type 16 E7 oncoprotein
59. Human papillomaviruses in the pathogenesis of anogenital cancer
60. Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras
61. Viral vectors for gene transfer into antigen presenting cells
62. Worldwide epidemiology of human adenovirus infections
63. Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues
64. Immunology of gene therapy with adenoviral vectors in mouse skeletal muscle
65. Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs
66. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers
67. The duration of antigenic stimulation determines the fate of naive and effector T-cells
68. In vivo detection of dendritic cell antigen presentation to CD4+ T-cells
69. Dendritic cell apoptosis during antigen-specific interaction with CD4+ T-cells
70. Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer